Navigation Links
Investor Call Scheduled to Discuss Ouster Proposal of Trinity Biotech Directors
Date:10/27/2008

KANSAS CITY, Mo., Oct. 27 /PRNewswire/ -- Thomas Reidy, an investor in Trinity Biotech plc (Nasdaq: TRIB), an Ireland-based developer and manufacturer of diagnostic products whose American Depository Receipts are traded on NASDAQ, will host an investor conference call November 3, 2008, at 10:00am EST, to discuss the recent shareholder proposal calling for the removal and replacement of Trinity Biotech's current directors.

On October 16, 2008, Mr. Reidy, and nine other shareholders, sent a letter to Trinity Biotech requesting that a special meeting of shareholders be held to consider the immediate removal of the current directors of Trinity Biotech. In the same letter, the investor group, who collectively hold beneficial ownership of more than 10% of Trinity Biotech's voting stock, directed that Trinity Biotech shareholders be given the opportunity to vote on the following slate of replacement directors:

-- Dr. Jack C. Chow, M.D., M.B.A. -- Partner, CRV Capital, LLC and adjunct

professor at Carnegie Mellon University's Heinz School of Public Policy

and Management;

-- Mr. Mike Gausling -- Managing Partner, Originate Ventures;

-- Dr. John H. Halsey, Ph.D. -- Chief Executive Officer, Director,

Founder, ProGene Biomedical, Inc. (dba IBT Laboratories);

-- Mr. Steven A. Mock, CPA -- Partner, BKD, LLP;

-- Mr. Thomas Reidy; and

-- Mr. Clint Severson -- Chairman, President and CEO of Abaxis, Inc.

According to Irish Law, Trinity Biotech must call a special meeting of shareholders, called an Extraordinary General Meeting, if the meeting is requested by shareholders holding in excess of 10% of the voting paid-up capital of the company.

The purpose of the confer
'/>"/>

SOURCE Thomas J. Reidy, Kansas City
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
2. GenVault to Present at the BIOCOM Investor Conference
3. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
4. China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries
5. BioAtom Inc. To Present at BIOCOM Investor Conference 2008
6. Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum
7. Oncothyreon to present at BIO Investor Forum 2008
8. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
9. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
10. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
11. WaferGen to Present at the Seventh Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... California (PRWEB) October 23, 2014 ... a specialty pharmaceutical company devoted to bringing new ... partnerships in 2015. , ViaDerma has developed an ... allows for rapid mass transfer of pharmaceutical active ... body to provide immediate localized therapy. The transdermal ...
(Date:10/25/2014)... 24, 2014 The Workgroup ... leading nonprofit authority on the use of health ... announces its appointment of four new co-chairs to ... leaders include:, ,     Peter Dumont, Senior ... Pupo, Specialist Leader, Deloitte Consulting LLP , ...
(Date:10/25/2014)... A new way to produce engineered skin not ... grafting technologies, it also speeds up the healing process, ... the October issue of STEM CELLS Translational Medicine, could ... result from severe burns and chronic wounds. , A ... These wounds heal by contraction, with epithelization (the process ...
(Date:10/25/2014)... ROCKVILLE, Md. , Oct. 24, 2014  RegeneRx Biopharmaceuticals, ... on data presented at the Fourth International Symposium on ... , Italy.  "When thymosin beta ... was injected into the peritoneal cavity in a rodent ... vessels and throughout the brain parenchyma (the functional tissue ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... 13 , - Regulated Information, ThromboGenics ... innovative treatments for vascular disease, eye disease and,cancer, ... three month period ended,31 March 2008., Prof. ... on,today,s announcement, said: "ThromboGenics, clinical development programs,are continuing ...
... Nile Therapeutics, Inc.,(Nasdaq: NLTX ), today announced that ... the Rodman & Renshaw 5th Annual Global Healthcare,Conference at ... Meridian Beach,Plaza Hotel in Monte Carlo, Monaco. Mr. Strumph ... of Nile,s current clinical development,programs., The presentation will ...
... Foam Technology with Improved Usability & ... ... Despite the high incidence,of women,s health conditions that require intra-vaginal drug ... survey,found that an alarming majority of women find their current treatment,options ...
Cached Biology Technology:ThromboGenics N.V. - Business Update 2ThromboGenics N.V. - Business Update 3ThromboGenics N.V. - Business Update 4ThromboGenics N.V. - Business Update 5ThromboGenics N.V. - Business Update 6ThromboGenics N.V. - Business Update 7Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 272% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds 2
(Date:10/22/2014)... 2014 The Nano-Bio Manufacturing Consortium (NBMC), an ... Laboratory (AFRL), has chosen a project proposed by the ... of Arizona College of Medicine – Tucson ... goal is to assess different sweat collection methods and ... sweat under a variety of human-body conditions, the results ...
(Date:10/18/2014)... Among a group of 2,000 patients referred for ... a potential molecular diagnosis for 25 percent, including ... and new mutations contributing to disease, according to ... study is being released to coincide with the ... Whole-exome sequencing analyzes the exons or coding regions ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... Standards and Technology (NIST) and the German national ... sensor to successfully track a human heartbeat, confirming ... in Applied Physics Letters, * the study ... resembling a clinical setting with the NIST mini-sensors, ...
... Earth,s radiation balance by interacting with solar radiation ... organic compounds are key players in new particle ... role as the newly formed particles cool our ... aerosol (SOA) particles formed from volatile compounds emitted ...
... CAOCT. 13, 2010 -- Alzheimer,s disease (AD) is an ... in its cause and progression. For example, the lipid-transport ... factor for AD, and apoE4 carriers account for 65󈞼% ... to the disease is unclear. Scientists at ...
Cached Biology News:NIST mini-sensor traces faint magnetic signature of human heartbeat 2New research results change the understanding of atmospheric aerosol properties and climate effects 2Gladstone scientists uncover mechanism for the major genetic risk factor of Alzheimer's disease 2
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... has been developed for use with ... of nonspecific background staining due to ... blocking peroxidase with hydrogen peroxide. ... combination with additional novel components to ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: